BridgeMD
New treatment option for Acute Lymphoid Leukemia
Official title Study of the Medullary Microenvironment in Acute Childhood Leukemia
ClinicalTrials.gov ID: NCT05792007
What this study is testing
- What it's testing
- Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 15. Healthy volunteers may be eligible.
You may be able to join if
- for patients with AL:
- Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
- Not having received prior hematological treatment
- Aged 1 to 15 years old
- Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
You likely can't join if
- for patients with AL:
- Patient under 1 year old and over 15 years old.
- Contraindication to myelogram.
- Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
- Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
- Having received prior hematological treatments.
See the full eligibility criteria
- for patients with AL:
- Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
- Not having received prior hematological treatment
- Aged 1 to 15 years old
- Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
- Affiliated patient or beneficiary of a social security scheme.
- Control group patients:
- Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
- Aged between 1 and 15 years old.
- Having no pathology of hematological origin.
- Not having received any treatment that could interfere with the functioning of the bone marrow.
- Whose 2 parents or the holder of parental authority have signed a consent enlightened.
- Affiliated patient or beneficiary of a social security scheme.
- for patients with AL:
- Patient under 1 year old and over 15 years old.
- Contraindication to myelogram.
- Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
- Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
- Having received prior hematological treatments.
- Parents with physical or mental condition not allowing to understand the informed consent.
- Control group patients
- Patient under 1 year old and over 15 years old.
- Having an underlying haematological pathology.
- Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
- Having received prior hematological treatments.
- Parents with physical or mental condition not allowing to understand informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Tours, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 15 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tours, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.